Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis.
about
Low frequency of mutations in the core promoter and precore regions of hepatitis B virus in anti-HBe positive Brazilian carriersKASL clinical practice guidelines: management of chronic hepatitis BDirect acting antivirals for the treatment of chronic viral hepatitisLamivudine/Adefovir Treatment Increases the Rate of Spontaneous Mutation of Hepatitis B Virus in PatientsStealth and cunning: hepatitis B and hepatitis C viruses.Genetic variations of the hepatitis B virus and their clinical relevanceAsian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.High frequency of the 1896 precore mutation in patients and blood donors with hepatitis B virus infection from the Indian subcontinent.Development of a molecular-beacon assay to detect the G1896A precore mutation in hepatitis B virus-infected individuals.Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combinationUnderstanding the Complex Patterns Observed during Hepatitis B Virus Therapy.Prevalence and Characteristics of Precore Mutation in Iran and Its Correlation with Genotypes of Hepatitis B.HBeAg negative variants and their role in the natural history of chronic hepatitis B virus infection.Immune tolerance split between hepatitis B virus precore and core proteins.Association of core promoter mutations of hepatitis B virus and viral load is different in HBeAg(+) and HBeAg(-) patients.Clinical efficacy of a 24-months course of lamivudine therapy in patients with HBeAg negative chronic hepatitis B: a long-term prospective study.Pathogenesis of hepatitis B virus infectionThe precore gene of the woodchuck hepatitis virus genome is not essential for viral replication in the natural hostPrecore stop mutant in HBeAg-positive patients with chronic hepatitis B: clinical characteristics and correlation with the course of HBeAg-to-anti-HBe seroconversion.Hepatitis B virus precore mutation and fulminant hepatitis in the United States. A polymerase chain reaction-based assay for the detection of specific mutation.Early termination of immune tolerance state of hepatitis B virus infection explains liver damage.TGF-β1 down-regulation of NKG2D/DAP10 and 2B4/SAP expression on human NK cells contributes to HBV persistenceClinical significance of hepatitis B virus (HBV) genotypes and precore and core promoter mutations affecting HBV e antigen expression in TaiwanMathematical models of e-antigen mediated immune tolerance and activation following prenatal HBV infection.World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants.Outbreak of hepatitis B virus infections associated with assisted monitoring of blood glucose in an assisted living facility-Virginia, 2010.Potent antiviral therapy improves survival in acute on chronic liver failure due to hepatitis B virus reactivation.Immune response and tolerance during chronic hepatitis B virus infection.A336C/A336T/T337C variations in HBV core gene and spontaneous hepatitis B e antigen loss in chronic hepatitis B patientsEuropean multicenter evaluation of high-density DNA probe arrays for detection of hepatitis B virus resistance mutations and identification of genotypesExpertise of laboratories in viral load quantification, genotyping, and precore mutant determination for hepatitis B virus in a multicenter study.The chimpanzee model for hepatitis B virus infection.Clinical relevance of hepatitis B virus variantsThe level of viral antigen presented by hepatocytes influences CD8 T-cell function.In vitro study of the effects of precore and lamivudine-resistant mutations on hepatitis B virus replication.Quantitative dynamics of hepatitis B basal core promoter and precore mutants before and after HBeAg seroconversion.The hepatitis B virus core and e antigens elicit different Th cell subsets: antigen structure can affect Th cell phenotype.Universal emergence of precore mutant hepatitis B virus along with seroconversion to anti-HBe irrespective of subsequent activity of chronic hepatitis B.Emerging treatments in chronic hepatitis B.Reactivation of hepatitis B virus with rituximab.
P2860
Q24801344-74D7D7FC-44BA-4601-B589-8E0A549DD6BFQ26752475-C9D5006E-C152-4B97-A5D1-D93E80EA9778Q27022216-E7539CA9-D416-408F-833E-846E7AFD3183Q27468616-AF647346-6337-4A37-BF61-DABCACD58845Q27470232-6F8981ED-9854-4306-9046-F2B2C3BFDC8BQ28298591-775BD96A-DFA4-40F4-AAF7-5F20290C8D84Q30391932-405EFEE5-642B-4D16-B82C-86EB97D0D380Q33204408-F2C6D760-E6A9-45F7-B9BF-1FDEFAAE7221Q33592384-7905243F-2E0F-4BE5-AEFA-5F4A11B6FFD2Q33651263-67766226-385E-4F6B-8605-16A70752654DQ33753991-9417AF53-229D-4B0B-A8CE-C78D0C41A248Q33764123-E950D825-6B80-47E8-BFF9-6B0AA625E422Q33801305-9CF9DED7-0CF1-42AE-AAA3-F1061841D7B6Q33835018-35C389C7-0076-48FA-9181-B7C6DADDAB72Q33841903-33D070BA-8D65-4933-A06D-84A29640911CQ33879651-7CEC2883-8223-4D00-8157-8E997FDB2C13Q33925491-37529E01-936A-4E47-BF73-021B3E63A274Q33937762-834D4A62-AC42-41BC-9D10-95249473543AQ33945490-F504A96E-8881-46DA-A925-91DC9637A666Q34124642-4FA005B7-ECB4-4F58-9AAD-A74823F50457Q34179245-F6FA862F-6447-463A-99D3-8D6B7F1A8481Q34205905-ADDEC8CA-8E5A-4F29-B723-67A1935849E9Q34231638-B1C0FC36-43ED-4992-BDC7-48C3A5281905Q34328969-016CCE2F-FBC8-4A5C-ADEE-64ADC909FBBBQ34536159-8FC66D4E-33BC-41C6-99D1-EC1768B8A6B8Q34539997-EF556A18-2362-4EBD-8365-0E34131F9D96Q34552034-26C636C3-CC26-42AC-8AFA-D366A8A38EFEQ34700332-7B7AF98F-2956-4E26-8264-BA3999A17602Q35053121-1149A414-6607-48FA-A6C2-DC50B53B6CE1Q35073136-90D8BD3C-52E7-4B70-AD65-571C01F7AAEAQ35073559-760CC688-8917-47D7-9B45-214ADE46776FQ35664171-68593DA0-8978-4DB5-9071-632F71A614D1Q35668730-54DFE4C9-C76B-4BCD-A8DF-93014A60529BQ35784981-930B84EB-209D-40BB-A32E-D6BBE629EEFDQ35785174-8CD65865-74C6-4745-BCF7-6E83F6B390E0Q35840358-FF83E607-CE54-49D3-AEF7-AE133A54F2E5Q35879066-C805ACB0-7D74-4A8C-AB06-2B78AF88F912Q35938992-608D417E-2FB6-41A3-A82E-CB02F3906E2DQ35967369-479967CB-E34F-4A2D-A6CF-972D00003ADFQ36150595-E072B964-F5E6-4089-B398-76F583B22F97
P2860
Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 1991
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis.
@en
Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis.
@nl
type
label
Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis.
@en
Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis.
@nl
prefLabel
Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis.
@en
Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis.
@nl
P2093
P2860
P356
P1476
Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis
@en
P2093
A Alfarano
E Chiaberge
M M Giarin
P2860
P304
P356
10.1073/PNAS.88.10.4186
P407
P577
1991-05-01T00:00:00Z